SPRYARS Pharmaceuticals, Inc.
$4.03-59% 1Y
$4.03
$3.9552 weeks$13.06
Is the price fair?
What SPRY's price assumes
ARS Pharmaceuticals, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 6.81× revenue.
6.81
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 63.7
Price / book · as of 2026-Q2
- EV / sales
- 6.41
EV / sales
Details›
- Price / bookas of 2026-Q2
- 63.7
- EV / EBIToperating margin −185%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q2
- 6.41
- Market capitalisation99.4 million shares, counted Aug 11, 2026
- $400M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.